Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy

被引：2
|
作者：
Panagiotou, Marios [1 ]
Koulouris, Nikolaos [1 ]
Koutsoukou, Antonia [1 ]
Tsami, Maria [2 ]
Syrigou, Ekaterini [3 ]
Rovina, Nikoletta [1 ]
机构：
[1] Univ Athens, Dept Resp Med 1, Sotiria Thorac Dis Gen Hosp, Athens, Greece
[2] Sotiria Gen Hosp, Dept Allergy & Clin Immunol, Athens, Greece
[3] Sotiria Gen Hosp, Dept Allergy & Clin Immunol, Athens, Greece
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
Asthma; -; management; Physical activity; Adults;
D O I：
10.1183/13993003.congress-2019.PA1648
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA1648
引用
收藏
页数：2
相关论文
共 49 条
  • [1] Anti-IL5 therapy for severe asthma: Towards a MAB war?
    Le Borgne-Krams, A.
    Guilleminault, L.
    Mailhol, C.
    Didier, A.
    REVUE FRANCAISE D ALLERGOLOGIE, 2016, 56 (7-8): : 549 - 555
  • [2] Late Breaking Abstract- Comparative Effectiveness of Anti-IL5/5R Versus Anti-IgE in Patients Eligible for Both (FIRE)
    Ali, Nasloon
    Lyu, Juntao
    Newell, Anthony
    Sadatsafavi, Mohsen
    Tran, Trung N.
    Price, David B.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [3] Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy
    Kroes, Johannes A.
    Zielhuis, Sybrand W. J.
    De Jong, Kim
    Zielhuis, Sander W.
    Van Roon, Eric N.
    Bel, Elisabeth H. D.
    Ten Brinke, Anneke
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [4] Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma
    Van Hulst, Glenn
    Jorssen, Joseph
    Jacobs, Nathalie
    Henket, Monique
    Louis, Renaud
    Schleich, Florence
    Bureau, Fabrice
    Desmet, Christophe
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [5] Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
    Laorden Escudero, Daniel
    Zamarron De Lucas, Ester
    Romero Ribate, David
    Fernandez Lahera, Juan
    Garcia Rio, Francisco
    Villasante Fernandez, Carlos
    Alvarez-Sala Walther, Rodolfo
    Quirce Gancedo, Santiago
    Padilla Brito, Jose Manuel
    Barranco Sanz, Pilar
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [6] Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma
    AlShareef, Saad
    McDonald, Christine F.
    Lee, Joy
    JOURNAL OF ASTHMA AND ALLERGY, 2022, 15 : 209 - 217
  • [7] Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy
    Maglio, Angelantonio
    Vitale, Carolina
    Pellegrino, Simona
    Calabrese, Cecilia
    Parente, Roberta
    Triggiani, Massimo
    Stellato, Cristiana
    Pelaia, Corrado
    Pelaia, Girolamo
    Vatrella, Alessandro
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [8] Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma
    Kavanagh, Joanne
    Roxas, Cris
    Green, Linda
    Fernandes, Mariana
    Thomson, Louise
    Payne, Victoria
    Hearn, Andrew
    Kent, Brian D.
    D'Ancona, Grainne
    Dhairwal, Jaideep
    Nanzer, Alexandra M.
    Jackson, David J.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [9] Overall response to anti-IL5/anti-IL5Rα treatment in severe asthma does not depend on initial bronchodilator responsiveness
    Mummler, C.
    Suhling, H.
    Kneidinger, N.
    Buhl, R.
    Kayser, M.
    Drick, N.
    Behr, J.
    Welte, T.
    Korn, S.
    Milger, K.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [10] Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma
    Jang, Jae-Hyuk
    Woo, Seong-Dae
    Lee, Youngsoo
    Kim, Chang-Keun
    Shin, Yoo Seob
    Ye, Young-Min
    Park, Hae-Sim
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2021, 13 (02) : 330 - 338
12345